Table 4 Univariate and multivariate analysis of clinico-pathological parameters for the prediction of cancer-specific survival in patients with operable pancreatic cancer (n=110)

From: Increased neutrophil-lymphocyte ratio is a poor prognostic factor in patients with primary operable and inoperable pancreatic cancer

 

Univariate analysis

Multivariate analysis

Parameter

HR (95% CI)

P -value

HR (95% CI)

P -value

Gender

Female

1 (referent)

0.641

1 (referent)

0.252

Male

0.901(0.583–1.394)

 

0.771 (0.494–1.203)

 

Age at operation (years)

<65

1 (referent)

0.102

1 (referent)

0.066

65

1.440 (0.930–2.229)

 

1.522 (0.973–2.379)

 

Stage at diagnosis

Stage I/IIa

1 (referent)

<0.001

1 (referent)

0.001

Stage IIb/III

3.686 (2.006–6.770)

 

2.923 (1.563–5.466)

 

Treatment

No chemotherapy

1 (referent)

0.069

NI

 

Chemotherapeutic treatment

0.779 (0.596–1.020)

   

Neutrophil-lymphocyte ratio

<5

1 (referent)

0.006

1 (referent)

0.039

5

1.852 (1.198–2.865)

 

1.611 (1.024–2.534)

 

Glasgow prognostic score

0

1 (referent)

0.585

NI

 

1+2

1.095 (0.791–1.516)

   

Platelet-lymphocyte ratio

<150

1 (referent)

0.458

NI

 

150

1.133 (0.815–1.574)

   

Resection margin

R0

1 (referent)

0.019

1 (referent)

0.073

R1

1.884 (1.110–3.199)

 

1.699 (0.951–3.035)

 
  1. Abbreviations: CI=confidence interval; HR=hazard ratio; NI=not included into multivariate analysis.